Clean Copy of Amended Claims 1-5 and 9-10

1 (three times amended). A mouse comprising a genome comprising a) exactly one functional elastin gene and b) either one mouse elastin gene comprising a null mutation or no second elastin gene.

2 (amended). A mouse comprising i) a genome with no elastin gene or ii) a genome with a) an elastin gene comprising a null mutation and b) no functional elastin gene.

3 (three times amended). A mouse cell comprising a genome comprising a) exactly one functional elastin gene and b) one mouse elastin gene comprising a null mutation or no second elastin gene.

4 (amended). A mouse cell comprising i) a genome with no elastin gene or ii) a genome with a) an elastin gene comprising a null mutation and b) no functional elastin gene.

5 (twice amended). A method to screen for drug candidates useful for treating humans with SVAS, hypertension or atherosclerosis or useful for preventing atherosclerosis in humans, said method comprising administering said drugs to an *ELN* +/- mouse or human, wherein said *ELN* +/- mouse or human comprises a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, wherein drugs which inhibit occlusion of arteries in said organism are said drug candidates.

9 (twice amended). A method to screen for a drug candidate useful for treating atherosclerosis, hypertension or SVAS in a human, said method comprising treating an *ELN* +/- mouse or human or *ELN* +/- mouse or human cells, wherein said *ELN* +/- mouse or human or mouse or human cells comprise a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, with drugs and measuring

synthesis of elastin RNA wherein a drug which increases synthesis of elastin RNA in said organisms or in said cells is said drug candidate.

10 (amended). A method to screen for a drug candidate useful for treating atherosclerosis, hypertension or SVAS in a human, said method comprising treating *ELN* +/- mice or *ELN* +/- mouse cells, wherein said *ELN* +/- mice or mouse cells comprise a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, with drugs and measuring synthesis of elastin wherein a drug which increases synthesis of elastin is said drug candidate.